Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
F-star Therapeutics, Inc. stock logo
FSTX
F-star Therapeutics
$7.12
$6.19
$2.07
$7.12
$156.50M0.85709,213 shsN/A
InflaRx stock logo
IFRX
InflaRx
$0.73
-59.9%
$1.35
$0.71
$2.82
$49.04M1.57260,286 shs7.97 million shs
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
$0.56
+4.5%
$0.44
$0.27
$1.14
$25.55M-0.052.12 million shs187,170 shs
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$0.54
-5.8%
$0.51
$0.38
$9.36
$49.93M1.73582,771 shs201,198 shs
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
F-star Therapeutics, Inc. stock logo
FSTX
F-star Therapeutics
0.00%0.00%0.00%0.00%0.00%
InflaRx stock logo
IFRX
InflaRx
-59.86%-56.78%-40.12%-47.26%-49.97%
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
+4.53%+14.17%+21.19%+66.13%-49.25%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-5.78%-15.31%+16.31%-8.52%-93.59%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
F-star Therapeutics, Inc. stock logo
FSTX
F-star Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
InflaRx stock logo
IFRX
InflaRx
2.7303 of 5 stars
3.53.00.00.03.51.70.6
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
2.8706 of 5 stars
3.55.00.00.02.40.01.3
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
4.2614 of 5 stars
3.13.00.04.72.73.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
F-star Therapeutics, Inc. stock logo
FSTX
F-star Therapeutics
0.00
N/AN/AN/A
InflaRx stock logo
IFRX
InflaRx
3.00
Buy$8.501,063.59% Upside
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
3.00
Buy$4.00616.59% Upside
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
2.20
Hold$8.001,382.03% Upside

Current Analyst Ratings Breakdown

Latest VRCA, IPA, FSTX, and IFRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/8/2025
InflaRx stock logo
IFRX
InflaRx
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$6.00
4/29/2025
InflaRx stock logo
IFRX
InflaRx
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$10.00
4/11/2025
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
4/9/2025
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
4/8/2025
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
4/1/2025
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSpeculative Buy ➝ Speculative Buy$3.00 ➝ $3.00
3/31/2025
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$7.00 ➝ $5.00
3/26/2025
InflaRx stock logo
IFRX
InflaRx
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $10.00
3/21/2025
InflaRx stock logo
IFRX
InflaRx
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
3/14/2025
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
F-star Therapeutics, Inc. stock logo
FSTX
F-star Therapeutics
$21.17M7.39N/AN/A$4.70 per share1.51
InflaRx stock logo
IFRX
InflaRx
$129.75K377.96N/AN/A$1.89 per share0.39
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
$24.00M1.06N/AN/A$0.93 per share0.60
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$7.18M6.95N/AN/A$0.47 per share1.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
F-star Therapeutics, Inc. stock logo
FSTX
F-star Therapeutics
-$31.28M-$1.82N/AN/AN/AN/A-57.08%-42.40%N/A
InflaRx stock logo
IFRX
InflaRx
-$46.18M-$0.82N/AN/AN/A-33,362.70%-65.98%-56.86%8/14/2025 (Estimated)
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
-$20.13M-$1.16N/AN/AN/A-114.50%-73.74%-42.68%8/4/2025 (Estimated)
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$67M-$1.20N/AN/AN/A-625.06%-591.84%-141.63%8/13/2025 (Estimated)

Latest VRCA, IPA, FSTX, and IFRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$0.14-$0.10+$0.04-$0.10$2.53 million$3.44 million
5/7/2025Q1 2025
InflaRx stock logo
IFRX
InflaRx
-$0.18-$0.14+$0.04-$0.14$0.03 million$0.03 million
3/28/2025Q3 2025
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
-$0.06-$0.06N/A-$0.46$6.59 million$4.23 million
3/20/2025Q4 2024
InflaRx stock logo
IFRX
InflaRx
-$0.27-$0.09+$0.18-$0.09$0.13 millionN/A
3/11/2025Q4 2024
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$0.25-$0.24+$0.01-$0.24$1.30 million$0.34 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
F-star Therapeutics, Inc. stock logo
FSTX
F-star Therapeutics
N/AN/AN/AN/AN/A
InflaRx stock logo
IFRX
InflaRx
N/AN/AN/AN/AN/A
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
N/AN/AN/AN/AN/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
F-star Therapeutics, Inc. stock logo
FSTX
F-star Therapeutics
0.15
3.38
3.38
InflaRx stock logo
IFRX
InflaRx
N/A
5.31
4.61
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
0.36
1.01
0.85
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
N/A
1.34
1.22

Institutional Ownership

CompanyInstitutional Ownership
F-star Therapeutics, Inc. stock logo
FSTX
F-star Therapeutics
31.50%
InflaRx stock logo
IFRX
InflaRx
42.39%
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
6.70%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
42.45%

Insider Ownership

CompanyInsider Ownership
F-star Therapeutics, Inc. stock logo
FSTX
F-star Therapeutics
3.20%
InflaRx stock logo
IFRX
InflaRx
16.30%
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
6.83%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
42.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
F-star Therapeutics, Inc. stock logo
FSTX
F-star Therapeutics
8421.98 million21.28 millionNot Optionable
InflaRx stock logo
IFRX
InflaRx
6067.13 million56.19 millionOptionable
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
8045.77 million28.94 millionNot Optionable
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
4092.49 million26.18 millionOptionable

Recent News About These Companies

VRCA Q2 EPS Raised by Brookline Capital Management

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
F-star Therapeutics stock logo

F-star Therapeutics NASDAQ:FSTX

F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom.

InflaRx stock logo

InflaRx NASDAQ:IFRX

$0.73 -1.09 (-59.86%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$0.72 -0.01 (-1.44%)
As of 05/28/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

ImmunoPrecise Antibodies stock logo

ImmunoPrecise Antibodies NASDAQ:IPA

$0.56 +0.02 (+4.53%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$0.56 0.00 (-0.04%)
As of 05/28/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

Verrica Pharmaceuticals stock logo

Verrica Pharmaceuticals NASDAQ:VRCA

$0.54 -0.03 (-5.78%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$0.56 +0.02 (+2.82%)
As of 05/28/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.